Clinical trial
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus…
NCT00192270 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00192270 |
|---|---|
| Title | Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children |
| Official title | A Prospective, Open-label, Phase II, Multi-center Study of the Safety, Tolerability and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children, Aged 6 to 17 Years |
| Acronym | FluMist |
| Lead sponsor | MedImmune LLC, Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological |
| Interventions | CAIV-T |
| Enrollment | 498 |
| Start date | Oct 1, 2000 |
| Primary completion | Jan 1, 2001 |
| Completion | Jan 1, 2001 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 6, 2012 |
| Countries | Belgium, Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: